Cancer treatment and survivorship statistics, 2019
2019/06/11 by Kimberly D. Miller, Leticia Nogueira, Letícia Nogueira +7 · 32 citations
Medicine · Economics, Econometrics and Finance · #Cancer survivorship and care #Economic and Financial Impacts of Cancer #Multiple and Secondary Primary Cancers
paper · pdf · doi:10.3322/caac.21565
Abstract
The number of cancer survivors continues to increase in the United States because of the growth and aging of the population as well as advances in early detection and treatment. To assist the public health community in better serving these individuals, the American Cancer Society and the National Cancer Institute collaborate every 3 years to estimate cancer prevalence in the United States using incidence and survival data from the Surveillance, Epidemiology, and End Results cancer registries; vital statistics from the Centers for Disease Control and Prevention's National Center for Health Statistics; and population projections from the US Census Bureau. Current treatment patterns based on information in the National Cancer Data Base are presented for the most prevalent cancer types. Cancer-related and treatment-related short-term, long-term, and late health effects are also briefly described. More than 16.9 million Americans (8.1 million males and 8.8 million females) with a history of cancer were alive on January 1, 2019; this number is projected to reach more than 22.1 million by January 1, 2030 based on the growth and aging of the population alone. The 3 most prevalent cancers in 2019 are prostate (3,650,030), colon and rectum (776,120), and melanoma of the skin (684,470) among males, and breast (3,861,520), uterine corpus (807,860), and colon and rectum (768,650) among females. More than one-half (56%) of survivors were diagnosed within the past 10 years, and almost two-thirds (64%) are aged 65 years or older. People with a history of cancer have unique medical and psychosocial needs that require proactive assessment and management by follow-up care providers. Although there are growing numbers of tools that can assist patients, caregivers, and clinicians in navigating the various phases of cancer survivorship, further evidence-based resources are needed to optimize care.
Citations
Cited by
- Colorectal cancer statistics, 2020
- Breast cancer statistics, 2019
- Epidemiology of Cancer
- All-Cause and Cardiovascular Disease Mortality Among Breast Cancer Survivors in CLUE II, a Long-Standing Community-Based Cohort
- Survival prediction for stage I-IIIA non-small cell lung cancer using deep learning
- Effects of parental health shocks on children's school achievements: A register-based population study
- Raman spectroscopy in tandem with machine learning – based decision logic methods for characterization and detection of primary precancerous and cancerous cells
- The Regulatory Role of MicroRNAs in Breast Cancer. [europepmc]
- Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome. [europepmc]
- LINC02273 drives breast cancer metastasis by epigenetically increasing AGR2 transcription. [europepmc]
- Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer. [europepmc]
- Association of the Epithelial-Mesenchymal Transition (EMT) with Cisplatin Resistance. [europepmc]
- Medical Care Costs Associated with Cancer Survivorship in the United States. [europepmc]
- An updated systematic review and meta-analysis on adherence to mediterranean diet and risk of cancer. [europepmc]
- Morbidity and Mortality of Laparoscopic vs Open Total Gastrectomy for Clinical Stage I Gastric Cancer: The CLASS02 Multicenter Randomized Clinical Trial. [europepmc]
- Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. [europepmc]
- Depression and prostate cancer risk: A Mendelian randomization study. [europepmc]
- Colorectal Cancer Immunotherapy: Options and Strategies. [europepmc]
- Insights into the role of sialylation in cancer progression and metastasis. [europepmc]
- Long noncoding RNAs: functions and mechanisms in colon cancer. [europepmc]
- Association of First Primary Cancer With Risk of Subsequent Primary Cancer Among Survivors of Adult-Onset Cancers in the United States. [europepmc]
- Regulated cell death pathways in doxorubicin-induced cardiotoxicity. [europepmc]
- A single-cell atlas of liver metastases of colorectal cancer reveals reprogramming of the tumor microenvironment in response to preoperative chemotherapy. [europepmc]
- Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers. [europepmc]
- Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. [europepmc]
- Association of Daily Sitting Time and Leisure-Time Physical Activity With Survival Among US Cancer Survivors. [europepmc]
- Mechanisms of Chemotherapy-Induced Neurotoxicity. [europepmc]
- Cardiovascular Disease Risk Among Cancer Survivors: The Atherosclerosis Risk In Communities (ARIC) Study. [europepmc]
- Adipocyte-Derived Exosomal MTTP Suppresses Ferroptosis and Promotes Chemoresistance in Colorectal Cancer. [europepmc]
- Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. [europepmc]
- Hot and cold tumors: Immunological features and the therapeutic strategies. [europepmc]
- Wnt/β-catenin-driven EMT regulation in human cancers. [europepmc]
Related